Table 1.
Baseline characteristics in patients with different FHV-ASPECTS
| Characteristics | Subtle FVH-O- ASPECTS (n=49) |
Prominent FVH-O- ASPECTS (n=52) |
p Value | Subtle FVH-I-ASPCTS (n=64) |
Prominent FVH-I- ASPECTS (n=37) |
p Value |
|---|---|---|---|---|---|---|
| Age, (mean±SD) | 68.2±17.3 | 64.3±18.2 | 0.269 | 66.0±18.6 | 66.4±16.7 | 0.925 |
| Male, n(%) | 13(26.5) | 16(30.8) | 0.638 | 17(26.6) | 12(32.4) | 0.530 |
| Risk factors | ||||||
| Hypertension, n(%) | 35(71.4) | 35(67.3) | 0.654 | 44(68.8) | 26(70.3) | 0.873 |
| Diabetes, n(%) | 10(20.4) | 10(19.2) | 0.882 | 12(18.8) | 8(21.6) | 0.727 |
| Hyperlipidemia, n(%) | 16(32.7) | 19(36.5) | 0.682 | 21(32.8) | 14(37.8) | 0.609 |
| Stroke/TIA, n(%) | 7(14.3) | 2(3.8) | 0.086 | 7(10.9) | 2(5.4) | 0.347 |
| CAD, n(%) | 8(16.3) | 9(17.3) | 0.895 | 12(18.8) | 5(13.5) | 0.498 |
| CHF, n(%) | 7(14.3) | 3(5.8) | 0.152 | 8(12.5) | 2(5.4) | 0.250 |
| AF, n(%) | 23(46.9) | 23(44.2) | 0.785 | 30(46.9) | 16(43.2) | 0.724 |
| Initial NIHSS | 19.0(13.0–23.0) | 14.5(11.0–19.8) | 0.016* | 13.5(10.0–19.8) | 20.0(15.5–23.0) | 0.001* |
| SBP mmHg, median (IQR) | 156.4±35.5 | 151.9±32.2 | 0.511 | 154.2±33.5 | 153.8±34.7 | 0.960 |
| DBP mmHg, median (IQR) | 89.0±22.9 | 84.9±17.4 | 0.314 | 87.3±20.2 | 86.3±20.6 | 0.815 |
| Blood glucose, mM, median (IQR) |
132.5±52.1 | 132.3±38.9 | 0.983 | 127.4±39.9 | 140.9±53.5 | 0.154 |
| Cholesterol, mM, median (IQR) | 149.1±38.1 | 167.0±48.9 | 0.043* | 164.7±45.5 | 147.2±41.6 | 0.059 |
| Previous medications | ||||||
| Antiplatelet therapy, n(%) | 13(26.5) | 10(19.2) | 0.382 | 14(21.9) | 9(24.3) | 0.777 |
| Anticoagulation therapy, n(%) | 6(12.2) | 7(13.5) | 0.855 | 11(17.2) | 2(5.4) | 0.088 |
| Right side | 23(46.9) | 28(53.8) | 0.488 | 34(53.1) | 17(45.9) | 0.487 |
| TOTAL FVH -ASPECTS | 5.0(3.0–8.0) | 10.0(9.0–11.0) | <0.001* | 7.5(4.0–10.0) | 9(7.0–12.0) | 0.001* |
| Infarct Volume | 46.5(14.6–89.6) | 13.7(6.3–33.7) | 0.001* | 13.0(5.9–23.7) | 65.0(30.5–97.5) | <0.001* |
| ASITN (0–2) | 36(73.5) | 25(48.1) | 0.009* | 33(51.6) | 28(75.7) | 0.017 |
| oTICI (0–2a) | 36(73.5) | 26(50.0) | 0.015 | 39(60.9) | 23(62.2) | 0.903 |
| IV t-PA | 23(46.9) | 20(38.5) | 0.389 | 28(43.8) | 15(40.5) | 0.753 |
| ET methods | 0.789 | 0.818 | ||||
| IA tPA | 3(6.1) | 3(5.8) | 3(4.7) | 3(8.1) | ||
| MERCI | 26(53.1) | 23(44.2) | 33(51.6) | 16(43.2) | ||
| Solitaire | 8(16.3) | 12(23.1) | 12(18.8) | 8(21.6) | ||
| Other methods | 12(24.5) | 14(26.9) | 16(25.0) | 10(27.0) | ||
| HT | 19(38.8) | 13(25.0) | 0.137 | 15(23.4) | 17(45.9) | 0.019* |
| Discharge mRS≤2 | 3(6.1) | 16(30.8) | 0.002* | 17(26.6) | 2(5.4) | 0.009* |
Abbreviations: FVH-O-ASPECTS=FVH-ASPECTS score outside DWI-positive area; FVH-I-ASPECTS= FVH-ASPECTS inside DWI-positive area; TIA= transient ischemic attack; CAD= coronary artery disease; CHF= Chronic heart failure; AF=arterial fibrillation; SBP=systolic blood pressure; DBP= diastolic blood pressure; ET= Endovascular treatment; HT= hemorrhagic transformation.